ENTITY
Gilead Sciences

Gilead Sciences (GILD US)

142
Analysis
Health CareUnited States
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
more
bullishWuXi XDC Cayman
01 Apr 2025 11:11

Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed

WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...

Logo
350 Views
Share
15 Mar 2025 09:47

Legend Biotech (LEGN US): Ends 2024 on a Promising Note; Carvykti Growth Prospect Brightens

​Legend exceeds expectations with strong 4Q24 results. Carvykti is poised for accelerated growth with manufacturing capacity, geography, and...

Logo
639 Views
Share
bullishDoorDash
10 Mar 2025 13:29

S&P500/400/600/Equal-Weight Flows for March 2025 Rebalance

The S&P500/400/600 rebalance was largely as expected. Williams Sonoma was our "first" pick to get in. It did. APP was the obvious entry which we...

Logo
494 Views
Share
bullishGenuine Biotech
21 Feb 2025 03:11

Genuine Biotech (真实生物) Pre-IPO Tearsheet

​Genuine Biotech seeks US$100 million in Hong Kong IPO. We summarize the key facts, including its core products, management and pre-IPO investors...

Logo
468 Views
Share
bullishDaiichi Sankyo
21 Jan 2025 00:30

Daiichi Sankyo (4568 JP): US Approval for Second ADC Drug to Drive Accelerated Growth

​FDA approves Daiichi Sankyo's Datroway for second-line treatment of breast cancer. Supported by AstraZeneca's commercialization expertise, the...

Logo
342 Views
Share
x